Founded in 2016, Beijing Inno Medicine Co. Ltd. stands as a dynamic novel drug discovery, development and manufacturing company. As a national high-tech enterprise, Inno Medicine is committed to crafting precise and efficient diagnostic solutions and targeted medicine to address the most pressing unmet medical needs, thereby advancing medical care for the betterment of mankind.

The team led by the company founder Dr. Ma Qian has long been devoted to the R&D of targeted medicine based on pathological studies. Leveraging the enhanced safety and efficacy offered by targeted liposomal drug delivery, the team successfully created a nano-drug targeted delivery platform. This accomplishment led to, the approval of 16 patents and the establishment of a comprehensive independent intellectual property system. The significance of these outcomes were acknowledged by Beijing Anzhen Hospital affiliated to Capital Medical University as a pivotal research transfer project.

In the eight years since its founding, Inno Medicine has made remarkable strides, establishing its headquarters office and R&D center in Beijing, a GMP-compliant manufacturing facility in Shanghai. Today, it has become a pioneering global health technology company with one headquarters and several specialized centers. This strategic configuration grants Inno Medicine an integrated capacity encompassing pipeline R&D, GMP-compliant manufacturing, and drug product formulation.

Inno Medicine has been steadfastly cultivating our distinctive competitive edge – the proprietary nano-drug targeted delivery platform. We direct resources to pre-clinical studies of novel drugs, with a focus on addressing unmet clinical needs. Taking advantage of our clinical and commercial manufacturing capacity, we are expediting the R&D and commercialization of novel products. So far, we have independently established product pipelines on the treatment of cardiovascular and cerebrovascular diseases, brain glioma, etc. A clinical study is being conducted by Inno Medicine on the world's first targeted delivery drug designed to actively and precisely reverse the formation of atherosclerotic plaques. YN001 has received IND approval from the US FDA and China NMPA, becoming the world's first cardiovascular targeted drug to enter clinical trials, is expected to become the first cardiovascular drug in history to obtain FDA approval through Accelerated Approval, and become a disruptive treatment method in this field. Building on the successful experience with cardiovascular drugs, our efforts extend towards the discovery and development of more novel drugs with global intellectual property rights, to broaden our pipeline for a diverse array of diseases and offer more therapeutic options to patients.

Our mission, “innovation for a healthier world,” encapsulates the company's core value. Our Chinese name “Yin Nuo” reveals the cultural values of benevolence and unwavering dedication to perfection. Indeed, we are resolutely dedicated to the vision of “benevolence, innovation, eliminating pain worldwide.”